KAEL Gem-Vax posts promising NSCLC data; India expects vaccine market to soar;

> South Korea-based KAEL Gem-Vax, which we profiled in our report on promising pancreatic cancer drugs, has reported Phase II results of its GV1001 vaccine for Stage III non-small cell lung cancer. The company found GV1001 was well tolerated, immunizing the majority of NSCLC patients and establishing durable T-cell memory. A randomized trial is next. KAEL Gem-Vax release

> The Indian vaccine market is expected to grow 23% during 2011-2012, reaching $4.6 billion in revenue by 2017. Report

> Experts at the U.K.'s National Health Service are weighing whether they should recommend that all kids under 17 should get the flu shot. Report

> A vaccine injected directly into a pancreatic tumor could hold promise for patients whose cancer can't be surgically removed. The Phase I trial, which included just 6 patients, was conducted at the Cancer Institute of New Jersey. Article

And Finally... A new web-based reporting system could make vaccines more effective by speeding the data collection process following vaccination. Article

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan